Abouzed T, Althobaiti F, Abdelkhlek N, Eldomany E, Nasr N, Sadek K
Int J Environ Res Public Health. 2021; 18(18).
PMID: 34574650
PMC: 8466341.
DOI: 10.3390/ijerph18189726.
Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T
Oncol Lett. 2020; 19(4):2657-2666.
PMID: 32218816
PMC: 7068289.
DOI: 10.3892/ol.2020.11371.
Nishida T, Kataoka H
Cancers (Basel). 2019; 11(9).
PMID: 31510063
PMC: 6770328.
DOI: 10.3390/cancers11091339.
Zhang Q, Chen H, Lin Z, Lin J
J Pharm Anal. 2018; 1(3):166-174.
PMID: 29403695
PMC: 5760791.
DOI: 10.1016/j.jpha.2011.06.004.
Tien W, Chen J, Wu K
BMC Bioinformatics. 2017; 18(Suppl 3):42.
PMID: 28361715
PMC: 5374707.
DOI: 10.1186/s12859-017-1465-7.
Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers.
Braicu C, Burz C, Berindan-Neagoe I, Balacescu O, Graur F, Cristea V
Gastroenterology Res. 2016; 2(4):191-199.
PMID: 27942274
PMC: 5139741.
DOI: 10.4021/gr2009.07.1304.
Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y, Jang E, Choi Y, Kim J, Jeong S
Clin Mol Hepatol. 2016; 22(3):359-365.
PMID: 27729630
PMC: 5066378.
DOI: 10.3350/cmh.2016.0033.
Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.
Ofuji K, Saito K, Yoshikawa T, Nakatsura T
J Hepatocell Carcinoma. 2016; 1:35-42.
PMID: 27508174
PMC: 4918265.
DOI: 10.2147/JHC.S48517.
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y, Kataoka H
World J Gastroenterol. 2016; 22(1):275-83.
PMID: 26755876
PMC: 4698492.
DOI: 10.3748/wjg.v22.i1.275.
A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
Xu C, Yan Z, Zhou L, Wang Y
J Cancer Res Clin Oncol. 2013; 139(8):1417-24.
PMID: 23743582
DOI: 10.1007/s00432-013-1458-5.
High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y, Gao W, Man Y, Nagata S, Ho M
MAbs. 2012; 4(5):592-9.
PMID: 22820551
PMC: 3499300.
DOI: 10.4161/mabs.20933.
The role of glypican-3 in regulating Wnt in hepatocellular carcinomas.
Gao W, Ho M
Cancer Rep. 2012; 1(1):14-19.
PMID: 22563565
PMC: 3343874.
Induction of latency-associated peptide (transforming growth factor-β(1)) expression on CD4+ T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-α production in a transforming growth factor-β-dependent manner.
Boswell S, Sharif S, Alisa A, Pereira S, Williams R, Behboudi S
Immunology. 2011; 133(3):278-87.
PMID: 21426338
PMC: 3112337.
DOI: 10.1111/j.1365-2567.2011.03425.x.
Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma.
Akutsu N, Yamamoto H, Sasaki S, Taniguchi H, Arimura Y, Imai K
World J Gastroenterol. 2010; 16(28):3521-8.
PMID: 20653060
PMC: 2909551.
DOI: 10.3748/wjg.v16.i28.3521.
Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.
Behboudi S, Alisa A, Boswell S, Anastassiou J, Pathan A, Williams R
Br J Cancer. 2010; 102(4):748-53.
PMID: 20087354
PMC: 2837570.
DOI: 10.1038/sj.bjc.6605526.
Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.
Friedl A
Semin Cell Dev Biol. 2009; 21(1):66-71.
PMID: 19931629
PMC: 2824000.
DOI: 10.1016/j.semcdb.2009.11.013.
Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma.
Filmus J, Capurro M
Mol Diagn. 2005; 8(4):207-12.
PMID: 15887976
DOI: 10.1007/BF03260065.
